SN-38

Generic Name: SN-38

Brand Names: Trodelvy

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₀N_₂O_₅

CAS Number: 86639-52-3

Unique Ingredient Identifier: 0H43101T0J

Background: 7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan Irinotecan, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negative Breast Cancer, among others.

Indication: Investigated for use/treatment in colorectal cancer.

Associated Conditions: Hormone Receptor Positive Metastatic Breast Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Triple Negative Breast Cancers, Unresectable Triple-Negative Breast Carcinoma, Metastatic HR Positive, HER2/Neu Negative Breast Cancer, Unresectable Locally Advanced Triple-negative Breast Cancer, Unresectable, locally advanced HR Positive, HER2/Neu Negative Breast Cancer, Unresectable, locally advanced Hormone Receptor Positive Breast Carcinoma

Clinical Trials

Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

Phase 2

Not yet recruiting

Conditions: Salivary Gland Cancer
Thyroid Cancer

Interventions: Drug: Sacituzumab govitecan

First Posted Date: 2025-04-11

Last Posted Date: 2025-04-11

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 32

Registration Number: NCT06923826

Locations: 🇸🇬
National University Cancer Institute Singapore, Singapore, Singapore

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Phase 2

Not yet recruiting

Conditions: Recurrent Platinum Resistant Epithelial Ovarian Carcinoma
Recurrent Epithelial Endometrial Carcinoma
Recurrent Epithelial Cervical Carcinoma

Interventions: Drug: Sacituzumab govitecan

First Posted Date: 2025-03-10

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT06865677

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Sacituzumab Govitecan

First Posted Date: 2024-10-30

Last Posted Date: 2024-10-30

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 20

Registration Number: NCT06665178

Locations: 🇨🇦
BC Cancer - Vancouver Center, Vancouver, British Columbia, Canada

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Sacituzumab Govitecan Alone in the Treatment of Advanced Urothelial Cancer

Phase 3

Not yet recruiting

Conditions: Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Questionnaire Administration
Biological: Pembrolizumab
Biological: Sacituzumab Govitecan

First Posted Date: 2024-07-29

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 384

Registration Number: NCT06524544

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy

Phase 3

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Doxorubicin
Drug: Sacituzumab govitecan-hziy
Drug: Paclitaxel

First Posted Date: 2024-07-03

Last Posted Date: 2025-05-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 520

Registration Number: NCT06486441

Locations: 🇯🇵
The Cancer Institute Hospital Of JFCR, Tokyo, Japan
🇬🇷
St. Luke's Hospital, Thessaloniki, Greece
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, China

and more 150 locations

A Study of Sacituzumab Govitecan in People With Mesothelioma

Phase 2

Recruiting

Conditions: Mesothelioma
Mesotheliomas Pleural
Mesothelioma; Pleura

Interventions: Drug: Sacituzumab govitecan-hziy

First Posted Date: 2024-06-27

Last Posted Date: 2025-05-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 33

Registration Number: NCT06477419

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 4 locations

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Phase 1

Not yet recruiting

Conditions: Leptomeningeal Metastases

Interventions: Drug: Sacituzumab Govitecan
Drug: Pemetrexed

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-18

Lead Sponsor: Guangzhou Medical University

Target Recruit Count: 34

Registration Number: NCT06462092

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Phase 2

Not yet recruiting

Conditions: Brain Metastasis

Interventions: Drug: Sacituzumab Govitecan
Radiation: Radiotherapy

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-17

Lead Sponsor: Guangzhou Medical University

Target Recruit Count: 43

Registration Number: NCT06462079

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Phase 3

Recruiting

Conditions: Lung Diseases
Carcinoma, Non-Small-Cell Lung
Resectable Lung Non-Small Cell Carcinoma

Interventions: Drug: Cisplatin
Drug: Zimberelimab
Drug: Carboplatin
Drug: Sacituzumab govitecan

First Posted Date: 2024-05-28

Last Posted Date: 2025-04-10

Lead Sponsor: Fundación GECP

Target Recruit Count: 129

Registration Number: NCT06431633

Locations: 🇪🇸
Hospital General de Elche, Elche, Alicante, Spain
🇪🇸
ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain

and more 27 locations

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Early Phase 1

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Taxotere
Drug: Cytoxan
Drug: Trastuzumab deruxtecan
Drug: Sacituzumab govitecan
Drug: Xeloda
Drug: Fulvestrant
Drug: Ribociclib
Drug: Abemaciclib

First Posted Date: 2024-05-10

Last Posted Date: 2025-05-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 15

Registration Number: NCT06409390

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy